Evidence map›Paper›PMID 29273331›Full record

ArticleKidney international2018

Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.

Alejandro R Chade, Maxx L Williams, Erika Guise, Luke J Vincent, Taylor W Harvey, Marija Kuna, Fakhri Mahdi, Gene L Bidwell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Targeted nanotherapy for kidney diseases: a comprehensive review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Review
  7. Article
  8. Novel Drug Delivery Technologies and Targets for Renal Disease.Hypertension (Dallas, Tex. : 1979) · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Inflammation and Oxidative Damage in Ischaemic Renal Disease.Antioxidants (Basel, Switzerland) · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alejandro R ChadeDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA; Department of Radiology, University of Mississippi Medical Center, Jackson, Mississippi, USA. Electronic address: achade@umc.edu.
Maxx L WilliamsDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Erika GuiseDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Luke J VincentDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Taylor W HarveyDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Marija KunaDepartment of Biochemistry, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Fakhri MahdiDepartment of Neurology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Gene L BidwellDepartment of Biochemistry, University of Mississippi Medical Center, Jackson, Mississippi, USA; Department of Neurology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Jackson Memorial Hospital · USUniversity of Mississippi Medical Center · US

Funding

STRUCTURAL VASCULAR ADAPTATION OF THE MICROCIRCULATIONP01HL051971 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI RECKELHOFF, JANE F · 1993 to 2018
$39.4M
The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2013 to 2022
$23.4M
A Novel Protein Delivery System for Therapy of PreeclampsiaR01HL121527 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI BIDWELL, GENE LEFLORE · 2014 to 2023
$4.1M
Microcirculation in Renovascular HypertensionR01HL095638 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2010 to 2021
$3.9M
NHLBI NIH HHS P01 HL051971NHLBI NIH HHS R01 HL095638NHLBI NIH HHS R01 HL121527NIGMS NIH HHS P20 GM104357
6 · The paper itself

Abstract

We recently developed a therapeutic biopolymer composed of an elastin-like polypeptide (ELP) fused to vascular endothelial growth factor (VEGF) and showed long-term renoprotective effects in experimental renovascular disease after a single intra-renal administration. Here, we sought to determine the specificity, safety, efficacy, and mechanisms of renoprotection of ELP-VEGF after systemic therapy in renovascular disease. We tested whether kidney selectivity of the ELP carrier would reduce off-target binding of VEGF in other organs. In vivo bio-distribution after systemic administration of ELP-VEGF in swine was determined in kidneys, liver, spleen, and heart. Stenotic-kidney renal blood flow and glomerular filtration rate were quantified in vivo using multi-detector computed tomography (CT) after six weeks of renovascular disease, then treated with a single intravenous dose of ELP-VEGF or placebo and observed for four weeks. CT studies were then repeated and the pigs euthanized. Ex vivo studies quantified renal microvascular density (micro-CT) and fibrosis. Kidneys, liver, spleen, and heart were excised to quantify the expression of angiogenic mediators and markers of progenitor cells. ELP-VEGF accumulated predominantly in the kidney and stimulated renal blood flow, glomerular filtration rate, improved cortical microvascular density, and renal fibrosis, and was accompanied by enhanced renal expression of VEGF, downstream mediators of VEGF signaling, and markers of progenitor cells compared to placebo. Expression of angiogenic factors in liver, spleen, and heart were not different compared to placebo-control. Thus, ELP efficiently directs VEGF to the kidney after systemic administration and induces long-term renoprotection without off-target effects, supporting the feasibility and safety of renal therapeutic angiogenesis via systemic administration of a novel kidney-specific bioengineered compound.

Indexed as

Angiogenesis Inducing AgentsAnimalsApoptosisBiomarkersDisease Models, AnimalDrug CarriersFibrosisGlomerular Filtration RateInjections, IntravenousKidneyNeovascularization, PhysiologicPeptidesRecombinant Fusion ProteinsRenal Artery ObstructionRenal CirculationStem CellsAngiogenesis Inducing AgentsBiomarkersDrug CarriersPeptidesRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVEGFA protein, humandrug deliveryelastin-like polypeptideimagingrenal hemodynamicsrenal injuryrenovascular diseasevascular endothelial growth factor

Identifiers

PMID29273331
PMCPMC5866753
OpenAlexW2779759291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.